Amneal Pharmaceuticals (NASDAQ:AMRX) Sees Strong Trading Volume – Here’s Why

30 Jan 2026, 20:03 by Doug Wharley · The Cerbat Gem

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) saw an uptick in trading volume on Wednesday . 2,753,723 shares traded hands during trading, an increase of 81% from the previous session’s volume of 1,522,188 shares.The stock last traded at $13.9050 and had previously closed at $13.83.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMRX. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price objective (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Truist Financial set a $15.00 price objective on Amneal Pharmaceuticals in a report on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Finally, Barclays started coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.80.

View Our Latest Stock Analysis on AMRX

Amneal Pharmaceuticals Trading Down 3.0%

The stock’s fifty day moving average price is $12.82 and its two-hundred day moving average price is $10.83. The stock has a market capitalization of $4.30 billion, a P/E ratio of 684.34 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 131,856 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the sale, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 231,856 shares of company stock worth $2,743,724. Insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AMRX. BlackBarn Capital Partners LP grew its stake in Amneal Pharmaceuticals by 19.6% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after acquiring an additional 564,916 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Amneal Pharmaceuticals by 22.0% in the second quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock worth $10,779,000 after purchasing an additional 240,676 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Amneal Pharmaceuticals by 1,440.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock valued at $11,790,000 after buying an additional 1,062,045 shares during the last quarter. Walleye Capital LLC increased its stake in Amneal Pharmaceuticals by 26.9% during the 2nd quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock valued at $5,735,000 after purchasing an additional 150,104 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in Amneal Pharmaceuticals by 276.3% in the 2nd quarter. Squarepoint Ops LLC now owns 572,548 shares of the company’s stock worth $4,632,000 after acquiring an additional 420,398 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.